Pirtobrutinib is a small molecule drug developed by Redx Pharma Plc, targeting BTK C481S. Pirtobrutinib has received its first approval in the United States.

Soligenix disclosed that it has commenced the enrollment of patients for its Phase 2 trial (protocol number DUS-AUBD-01) investigating SGX945 (dusquetide).

Enlonstobart, a groundbreaking therapeutic agent, is a fully humanized monoclonal antibody developed by Hangzhou Shangjian Biotechnology Co., Ltd.

Merck obtains exclusive global rights for LM-299, a clinical investigational bispecific antibody targeting PD-1 and VEGF, from LaNova Medicines Ltd.

Sotorasib is an oral medication developed to target a specific mutation in the KRAS gene, known as KRAS G12C, which is implicated in various cancers.

Tune Therapeutics Enters Clinical Arena with TUNE-401: A Novel Epigenetic Silencer Targeting Hepatitis B.

Disitamab Vedotin is an antibody-drug conjugate (ADC) developed by Hengrui Medicine, targeting human epidermal growth factor receptor 2 (HER2).

Tirzepatide treatment in obese or overweight adults with pre-diabetes led to lasting weight reduction, with almost 99% staying free of diabetes after 176 weeks.

PLX-4545 is a molecular glue drug developed by Plexium, Inc. The drug targets IKZF2 and is intended for the treatment of neoplasms.

MoonLake Immunotherapeutics has launched Phase 3 of the IZAR program for the Nanobody® sonelokimab in individuals suffering from active psoriatic arthritis.

Mipomersen, developed by Isis Pharmaceuticals and marketed by Genzyme, is an antisense oligonucleotide that targets the apolipoprotein B-100 (ApoB-100) mRNA.

Gan & Lee Pharmaceuticals reported favorable Phase 1 outcomes for its oral GLP-1 receptor agonist, GZR18 tablet, in healthy subjects, showing a weight loss of 4.16% over two weeks.